Related Experiment Video

Updated: Jul 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Treatment for dyslipidemias in patients with arterial hypertension]

I E Chazova, V V Kukharchuk, L G Ratova

    Terapevticheskii Arkhiv
    |June 15, 2007
    PubMed

    Insights

    Rozuvastatin effectively improves lipid profiles and lowers blood pressure in patients with hypertension and dyslipidemia. A 10 mg daily dose was sufficient for most patients to normalize their lipid levels.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Internal Medicine

    Background:

    • Arterial hypertension (AH) and dyslipidemia are common comorbidities.
    • Effective management requires addressing both lipid profiles and blood pressure.

    Purpose of the Study:

    • To evaluate the combined effects of non-drug measures and rozuvastatin on lipid spectrum and blood pressure in patients with AH and dyslipidemia.

    Main Methods:

    • A multicenter, open-labeled, prospective study involving 279 patients (aged 56.7 ± 8.7 years) with AH and dyslipidemia.
    • Patients received rozuvastatin therapy for 12 weeks, alongside non-drug measures.
    • Blood pressure and lipid parameters were monitored throughout the study.

    Main Results:

    • Rozuvastatin significantly reduced total cholesterol, LDL cholesterol, triglycerides, and the atherogenicity index, while increasing HDL cholesterol.
    • Target LDL cholesterol levels were achieved in 61% of patients, HDL in 70%, and TG in 73%.
    • Significant reductions in body mass, BMI, waist circumference, and blood pressure (12.1/4.1 mm Hg) were observed.

    Conclusions:

    • Rozuvastatin is effective in improving lipid profiles and reducing blood pressure in patients with concurrent AH and dyslipidemia.
    • A daily dose of 10 mg rozuvastatin was sufficient to normalize lipid profiles in the majority of patients (83%).
    • Starting rozuvastatin therapy at 10 mg/day is recommended.
    Abstract

    Related Concept Videos

    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Atherosclerosis IV: Nursing Management01:23

    Atherosclerosis IV: Nursing Management

    Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...